1
|
Dill V, Blüm P, Lindemann A, Biederstädt A, Högner M, Götze KS, Bassermann F, Hildebrandt M. Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysis. Transfusion 2024; 64:871-880. [PMID: 38600674 DOI: 10.1111/trf.17829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 01/12/2024] [Accepted: 03/27/2024] [Indexed: 04/12/2024]
Abstract
BACKGROUND Despite recent advances in the treatment of multiple myeloma, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) remains an essential therapeutic keystone. As for the stem cell mobilization procedure, different regimens have been established, usually consisting of a cycle of chemotherapy followed by application of granulocyte-colony stimulating factor (G-CSF), although febrile neutropenia is a common complication. Following national guidelines, our institution decided to primarily use G-CSF only mobilization during the COVID-19 pandemic to minimize the patients' risk of infection and to reduce the burden on the health system. STUDY DESIGN AND METHODS In this retrospective single-center analysis, the efficacy and safety of G-CSF only mobilization was evaluated and compared to a historic control cohort undergoing chemotherapy-based mobilization by cyclophosphamide and etoposide (CE) plus G-CSF. RESULTS Although G-CSF only was associated with a higher need for plerixafor administration (p < .0001) and a higher number of apheresis sessions per patient (p = .0002), we were able to collect the target dose of hematopoietic stem cells in the majority of our patients. CE mobilization achieved higher hematopoietic stem cell yields (p = .0015) and shorter apheresis sessions (p < .0001) yet was accompanied by an increased risk of febrile neutropenia (p < .0001). There was no difference in engraftment after ASCT. DISCUSSION G-CSF only mobilization is a useful option in selected patients with comorbidities and an increased risk of serious infections, especially in the wintertime or in future pandemics.
Collapse
Affiliation(s)
- Veronika Dill
- Department of Internal Medicine III, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
| | - Philipp Blüm
- Department of Internal Medicine III, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany
- Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany
| | - Anja Lindemann
- TUMCells Interdisciplinary Center for Cellular Therapies, Technical University of Munich, School of Medicine, Munich, Germany
| | - Alexander Biederstädt
- Department of Internal Medicine III, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Marion Högner
- Department of Internal Medicine III, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany
| | - Katharina S Götze
- Department of Internal Medicine III, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
| | - Florian Bassermann
- Department of Internal Medicine III, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany
- Bavarian Cancer Research Center (BZKF), Munich, Germany
| | - Martin Hildebrandt
- Department of Internal Medicine III, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany
- Bavarian Cancer Research Center (BZKF), Munich, Germany
| |
Collapse
|
2
|
Hildebrandt M, Pham Thuy D, Kippenberger J, Wigger TL, Houston JE, Scotti A, Karg M. Fluid-solid transitions in photonic crystals of soft, thermoresponsive microgels. Soft Matter 2023; 19:7122-7135. [PMID: 37695048 DOI: 10.1039/d3sm01062g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/12/2023]
Abstract
Microgels are often discussed as well-suited model system for soft colloids. In contrast to rigid spheres, the microgel volume and, coupled to this, the volume fraction in dispersion can be manipulated by external stimuli. This behavior is particularly interesting at high packings where phase transitions can be induced by external triggers such as temperature in the case of thermoresponsive microgels. A challenge, however, is the determination of the real volume occupied by these deformable, soft objects and consequently, to determine the boundaries of the phase transitions. Here we propose core-shell microgels with a rigid silica core and a crosslinked, thermoresponsive poly-N-isopropylacrylamide (PNIPAM) shell with a carefully chosen shell-to-core size ratio as ideal model colloids to study fluid-solid transitions that are inducible by millikelvin changes in temperature. Specifically, we identify the temperature ranges where crystallization and melting occur using absorbance spectroscopy in a range of concentrations. Slow annealing from the fluid to the crystalline state leads to photonic crystals with Bragg peaks in the visible wavelength range and very narrow linewidths. Small-angle X-ray scattering is then used to confirm the structure of the fluid phase as well as the long-range order, crystal structure and microgel volume fraction in the solid phase. Thanks to the scattering contrasts and volume ratio of the cores with respect to the shells, the scattering data do allow for form factor analysis revealing osmotic deswelling at volume fractions approaching and also exceeding the hard sphere packing limit.
Collapse
Affiliation(s)
- M Hildebrandt
- Institut für Physikalische Chemie I: Kolloide und Nanooptik, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, D-40225 Düsseldorf, Germany.
| | - D Pham Thuy
- Institut für Physikalische Chemie I: Kolloide und Nanooptik, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, D-40225 Düsseldorf, Germany.
| | - J Kippenberger
- Institut für Physikalische Chemie I: Kolloide und Nanooptik, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, D-40225 Düsseldorf, Germany.
| | - T L Wigger
- Institut für Physikalische Chemie I: Kolloide und Nanooptik, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, D-40225 Düsseldorf, Germany.
| | - J E Houston
- European Spallation Source ERIC, Box 176, SE-221 00 Lund, Sweden
| | - A Scotti
- Institute of Physical Chemistry, RWTH Aachen University, Landoltweg 2, 52056 Aachen, Germany
| | - M Karg
- Institut für Physikalische Chemie I: Kolloide und Nanooptik, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, D-40225 Düsseldorf, Germany.
| |
Collapse
|
3
|
Wagner A, Wostrack M, Hartz F, Heim J, Hameister E, Hildebrandt M, Meyer B, Winter C. The role of extended coagulation screening in adult cranial neurosurgery. Brain Spine 2023; 3:101756. [PMID: 37383462 PMCID: PMC10293229 DOI: 10.1016/j.bas.2023.101756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 04/23/2023] [Accepted: 05/10/2023] [Indexed: 06/30/2023]
Abstract
Introduction Postoperative hemorrhage after adult cranial neurosurgery is a serious complication with substantial morbidity and mortality. Research question We investigated if an extended preoperative screening and an early treatment of previously undetected coagulopathies may decrease the risk of postoperative hemorrhage. Methods A prospective study cohort of patients undergoing elective cranial surgery and receiving the extended coagulatory work-up were compared to a propensity matched historical control cohort. The extended work-up included a standardized questionnaire on the patient's bleeding history as well as coagulatory tests of Factor XIII, von-Willebrand-Factor and PFA-100®. Deficiencies were substituted perioperatively. The primary outcome was determined as the surgical revision rate due to postoperative hemorrhage. Results The study cohort and the control cohort included 197 cases each, without any significant difference in the preoperative intake of anticoagulant medication (p = .546). Most common interventions were resections of malignant tumors (41%), benign tumors (27%) and neurovascular surgeries (9%) in both cohorts. Imaging revealed postoperative hemorrhage in 7 cases (3.6%) in the study cohort and 18 cases (9.1%) in the control cohort (p = .023). Of these, revision surgeries were significantly more common in the control cohort with 14 cases (9.1%) compared to 5 cases (2.5%) in the study cohort (p = .034). Differences in mean intraoperative blood loss were not significant with 528 ml in the study cohort and 486 ml in the control cohort (p = .376). Conclusion Preoperative extended coagulatory screening may allow for revealing previously undiagnosed coagulopathies with subsequent preoperative substitution and thereby reduction of risk for postoperative hemorrhage in adult cranial neurosurgery.
Collapse
Affiliation(s)
- Arthur Wagner
- Department of Neurosurgery, Technical University Munich School of Medicine, Munich, Germany
| | - Maria Wostrack
- Department of Neurosurgery, Technical University Munich School of Medicine, Munich, Germany
| | - Frederik Hartz
- Department of Neurosurgery, Technical University Munich School of Medicine, Munich, Germany
| | - Johannes Heim
- Department of Neurosurgery, Technical University Munich School of Medicine, Munich, Germany
| | - Erik Hameister
- Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich School of Medicine, Munich, Germany
| | - Martin Hildebrandt
- Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich School of Medicine, Munich, Germany
| | - Bernhard Meyer
- Department of Neurosurgery, Technical University Munich School of Medicine, Munich, Germany
| | - Christof Winter
- Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich School of Medicine, Munich, Germany
| |
Collapse
|
4
|
Priesner C, Hildebrandt M. Advanced Therapy Medicinal Products and the Changing Role of Academia. Transfus Med Hemother 2022; 49:158-162. [PMID: 35813600 PMCID: PMC9209977 DOI: 10.1159/000524392] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 03/21/2022] [Indexed: 09/22/2023] Open
Abstract
Academic institutions coin the ATMP landscape but do not possess an industry-like capacity to vigorously pursue the full developmental pathway to marketing authorization. At the same time, industry has fostered clinical trials with ATMPs, brought the first products to marketing authorization, and defined novel modes of interaction with academia. A regulatory niche for local manufacturing of ATMPs within an academic institution had been foreseen in Regulation (EU) 1394/2007 under the term "Hospital Exemption" but remained ill-defined. Manufacture in close proximity to the patient is difficult to accomplish, as "point of care" systems for the manufacture of ATMPs have encountered regulatory challenges hovering between process and product. The efforts and costs for the development of ATMPs continue to be dramatically underestimated, and few academic centers were persistent enough to invest in the GMP infrastructure needed and to recruit personnel trained in ATMP development. As a consequence, the contribution by hospitals to ATMP development has shifted from the finished ATMP toward the procurement of starting materials, selected manufacturing steps, storage of the product, clinical application, and participation in clinical trials. As the development and use of cell-based therapies and ATMPs continue to attract and challenge clinicians and scientists, this review aims to discuss logistical, financial, and regulatory issues that might contribute to the changing role of Academia in ATMP development, with an outlook into possible developments in the future and proposals for ways to reshape the academic environment under the auspices of what might truly have been meant by the hospital exemption clause.
Collapse
Affiliation(s)
- Christoph Priesner
- TUMCells Interdisciplinary Center for Cellular Therapies, Technical University of Munich, München, Germany
| | - Martin Hildebrandt
- Department of Internal Medicine III, Hematology and Oncology, Technical University of Munich Medical School, München, Germany
| |
Collapse
|
5
|
Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 2022; 33:259-275. [PMID: 34923107 DOI: 10.1016/j.annonc.2021.12.003] [Citation(s) in RCA: 130] [Impact Index Per Article: 65.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Accepted: 12/06/2021] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. DESIGN The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field. RESULTS Thirty-six CAR-T experts (medical, nursing, pharmacy/laboratory) assembled to draft recommendations to cover all aspects of CAR-T patient care and supply chain management, from patient selection to long-term follow-up, post-authorisation safety surveillance and regulatory issues. CONCLUSIONS We provide practical, clinically relevant recommendations on the use of these high-cost, logistically complex therapies for haematologists/oncologists, nurses and other stakeholders including pharmacists and health sector administrators involved in the delivery of CAR-T in the clinic.
Collapse
Affiliation(s)
- P J Hayden
- Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland
| | - C Roddie
- UCL Cancer Institute, London, UK; University College London Hospital NHS Foundation Trust, London, UK.
| | - P Bader
- Clinic for Children and Adolescents, University Children's Hospital, Frankfurt, Germany
| | - G W Basak
- Medical University of Warsaw, Department of Hematology, Transplantation and Internal Medicine, Warsaw, Poland
| | - H Bonig
- Institute for Transfusion Medicine and Immunohematology of Goethe University and German Red Cross Blood Service, Frankfurt, Germany
| | - C Bonini
- Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy
| | - C Chabannon
- Aix-Marseille université, Inserm CBT-1409, Institut Paoli-Calmettes, centre de thérapie cellulaire, unité de transplantation et de thérapie cellulaire, département de biologie du cancer, Marseille, France
| | - F Ciceri
- Università Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | - S Corbacioglu
- Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Franz-Josef-Strauss-Allee 11, University Hospital of Regensburg, Regensburg, Germany
| | - R Ellard
- Royal Marsden Hospital, Fulham Rd, London, UK
| | - F Sanchez-Guijo
- IBSAL-Hospital Universitario de Salamanca, CIC, Universidad de Salamanca, Salamanca, Spain
| | - U Jäger
- Clinical Department for Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - M Hildebrandt
- Department of Transfusion Medicine, Cell Therapeutics and Haemostaseology, LMU University Hospital Grosshadern, Munich
| | - M Hudecek
- Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
| | - M J Kersten
- Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE, Amsterdam, the Netherlands
| | - U Köhl
- Fraunhofer Institute for Cell Therapy and Immunology (IZI) and Institute of Clinical Immunology, University of Leipzig, Leipzig, Germany; Institute of Cellular Therapeutics, Hannover Medical School, Hannover, Germany
| | - J Kuball
- Department of Hematology and Centre for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - S Mielke
- Karolinska Institutet and University Hospital, Department of Laboratory Medicine/Department of Cell Therapy and Allogeneic Stem Cell Transplantation (CAST), Stockholm, Sweden
| | - M Mohty
- Hôpital Saint-Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, France
| | - J Murray
- Christie Hospital NHS Trust, Manchester, UK
| | - A Nagler
- The Chaim Sheba Medical Center, Tel-Hashomer, affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - J Rees
- University College London Hospital NHS Foundation Trust, London, UK; UCL Institute of Neurology, University College of London Hospitals NHS Foundation Trust, London, UK
| | - C Rioufol
- Hospices Civils de Lyon, UCBL1, EMR 3738 CICLY, Lyon, France
| | - R Saccardi
- Cell Therapy and Transfusion Medicine Department, Careggi University Hospital, Florence, Italy
| | - J A Snowden
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - J Styczynski
- Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland
| | - M Subklewe
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - C Thieblemont
- AP-HP, Saint-Louis Hospital, Hemato-oncology, University of Paris, Paris, France
| | - M Topp
- Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
| | - Á U Ispizua
- Department of Hematology, ICMHO, Hospital Clínic de Barcelona, Barcelona, Spain
| | - D Chen
- University College London Hospital NHS Foundation Trust, London, UK; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - R Vrhovac
- Department of Haematology, University Hospital Centre Zagreb, Zagreb, Croatia
| | - J G Gribben
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - N Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg, Germany
| | - H Einsele
- Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
| | - I Yakoub-Agha
- CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France
| |
Collapse
|
6
|
Ashford P, Chapman J, Hildebrandt M, Noël L, Pruett T, Slaper-Cortenbach I, Wilson D. Establishing consensus on ethics, traceability and biovigilance for medical products of human origin. Bull World Health Organ 2021; 99:907-909. [PMID: 34866688 PMCID: PMC8640690 DOI: 10.2471/blt.21.285484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 09/30/2021] [Accepted: 10/06/2021] [Indexed: 11/27/2022] Open
Affiliation(s)
- Paul Ashford
- International Council for Commonality in Blood Banking Automation, 1901 Orange Tree Lane Ste 200, Redlands, California 92374, United States of America (USA)
| | - Jeremy Chapman
- Westmead Institute for Medical Research, University of Sydney, Sydney, Australia
| | | | | | - Timothy Pruett
- Department of Surgery, University of Minnesota, Minneapolis, USA
| | | | | |
Collapse
|
7
|
Möhnle P, Humpe A, Boeck M, Gruetzner S, Hackstein H, Offner R, Hildebrandt M. Emergency Use of Convalescent Plasma: Perception of the Regulatory Framework from a Clinical Perspective. Transfus Med Hemother 2021; 49:119-124. [DOI: 10.1159/000519841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 09/08/2021] [Indexed: 11/19/2022] Open
Abstract
The pandemic spread of an infectious disease poses a plethora of challenges to society, clinicians, health care providers and regulating authorities. In order to mount a rapid response and to provide hope in a potentially catastrophic situation as the current COVID-19 pandemic, emergency plans, regulations and funding strategies have to be developed on regional, national and international levels. The speed needed to establish rapid response programs is challenged by the dynamics of the spread of the disease, the concurrent and competing development of different and potentially more effective treatment options, and not the least by regulatory uncertainty. Convalescent plasma, that is plasma collected from patients who have recovered from COVID-19 infections, has emerged as one of the first potential treatment options in the absence of drugs or vaccines with proven efficacy against SARS-CoV-2. The societal aspects of convalescent plasma and the public awareness gave an additional boost to the rapid employment of convalescent plasma donation platforms immediately after the SARS-CoV-2 outbreak. At the same time, uncertainty remains as to the efficacy of convalescent plasma. With evidence mostly limited to empirical reports, convalescent plasma has been used for decades for the prophylaxis and treatment of various infectious diseases. Clinical trials have addressed different infectious agents, stages of disease, target groups of patients and yielded sometimes inconclusive results. The aim of this short review is to delineate the regulatory background for the emergency use of convalescent plasma in the USA, in the European Union and in Germany, and the transition to the setting of clinical trials. In addition, we describe observations made in the process of collecting COVID-19 convalescent plasma (herein referred to as CCP), and formulate proposals to further improve the framework for rapid responses in future emergency situations.
Collapse
|
8
|
Spiekermann K, Subklewe M, Hildebrandt M, Humpe A, von Bergwelt-Baildon M. [Update 2021: COVID-19 from the Perspective of Haematology and Haemostaseology]. Dtsch Med Wochenschr 2021; 146:899-903. [PMID: 34256404 DOI: 10.1055/a-1449-4934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Infection with SARS-CoV-2 has a profound influence on the hematopoetic system that mediates clinical symptoms and mortality. Several studies have shown that treatment of the cytokine storm (CRS) with anti-inflammatory drugs like dexamethasone and tocilizumab can significantly improve survival. Systematic reviews confirm the safety of convalescent plasma administration and offer initial indications of its effectiveness in certain groups. COVID-associated coagulopathy (CAC) and vaccine-induced immune thrombotic thrombocytopenia (VITT) represent severe infection- or vaccination associated complications that require a specific diagnostic and therapeutic workup.
Collapse
|
9
|
Bücklein V, Blumenberg V, Ackermann J, Frölich L, Winkelmann M, Schmidt C, Rejeski K, Ruzicka M, Müller N, von Baumgarten L, Schöberl F, Hildebrandt M, Humpe A, Kunz W, Hoster E, von Bergwelt M, Subklewe M. EXTRANODAL DISEASE IS ASSOCIATED WITH SHORTER PROGRESSION‐FREE SURVIVAL AFTER CD19‐CAR T‐CELL THERAPY FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.183_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- V. Bücklein
- University Hospital LMU Munich Department of Medicine III Munich Germany
| | - V. Blumenberg
- University Hospital LMU Munich Department of Medicine III Munich Germany
| | - J. Ackermann
- University Hospital LMU Munich Department of Medicine III Munich Germany
| | - L. Frölich
- University Hospital LMU Munich Department of Medicine III Munich Germany
| | - M. Winkelmann
- University Hospital LMU Munich Department of Radiology Munich Germany
| | - C. Schmidt
- University Hospital LMU Munich Department of Medicine III Munich Germany
| | - K. Rejeski
- University Hospital LMU Munich Department of Medicine III Munich Germany
| | - M. Ruzicka
- University Hospital LMU Munich Department of Medicine III Munich Germany
| | - N. Müller
- University Hospital LMU Munich Department of Medicine III Munich Germany
| | - L. von Baumgarten
- University Hospital LMU Munich Department of Neurosurgery Munich Germany
| | - F. Schöberl
- University Hospital LMU Munich Department of Neurology Munich Germany
| | - M. Hildebrandt
- University Hospital LMU Munich Department of Transfusion Medicine Munich Germany
| | - A. Humpe
- University Hospital LMU Munich Department of Transfusion Medicine Munich Germany
| | - W. Kunz
- University Hospital LMU Munich Department of Radiology Munich Germany
| | - E. Hoster
- LMU Munich Institute for Medical Information Processing, Biometry, and Epidemiology Munich Germany
| | - M. von Bergwelt
- University Hospital LMU Munich Department of Medicine III Munich Germany
| | - M. Subklewe
- University Hospital LMU Munich Department of Medicine III Munich Germany
| |
Collapse
|
10
|
Hecker JS, Wahida A, Hameister E, Filo A, Ruland J, Bassermann F, Hildebrandt M, Verbeek M, Poeck H. ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations. eJHaem 2021; 2:280-284. [PMID: 35845280 PMCID: PMC9175969 DOI: 10.1002/jha2.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Revised: 03/10/2021] [Accepted: 03/12/2021] [Indexed: 11/30/2022]
Abstract
Allogeneic hematopoietic stem cell transplantations (HSCTs) represent a curative strategy for treating hematologic malignancies yet bear dangerous and frequently life‐threatening complications including the development of graft‐versus‐host disease. Here, we present a case of a patient that suffered from relapsed/refractory multiple myeloma, a hematologic neoplasm characterized by clonal proliferation of malignant plasma cells in the bone marrow. During the course of his disease, the patient underwent consecutive allogeneic HSCTs, during which he developed a clinical meaningful and hitherto unreported ABO subgroup incompatibility, leading to persistent hemolysis. Testing for ABO subgroups during donor selection, especially after consecutive allogeneic HSCTs, may therefore aid to prevent these complications.
Collapse
Affiliation(s)
- Judith S. Hecker
- Department of Medicine III, Hematology and Internal Oncology, TUM School of Medicine Technical University of Munich Munich Germany
| | - Adam Wahida
- Department of Medicine III, Hematology and Internal Oncology, TUM School of Medicine Technical University of Munich Munich Germany
- Torsten‐Haferlach‐Leukemia‐Diagnostics Foundation Munich Germany
| | - Erik Hameister
- Institute of Clinical Chemistry and Pathobiochemistry TUM School of Medicine Technical University of Munich Munich Germany
- Department of Medical Oncology and Hematology University of Zurich and University Hospital Zurich Zurich Switzerland
| | - Aneta Filo
- Institute of Clinical Chemistry and Pathobiochemistry TUM School of Medicine Technical University of Munich Munich Germany
| | - Jürgen Ruland
- Institute of Clinical Chemistry and Pathobiochemistry TUM School of Medicine Technical University of Munich Munich Germany
| | - Florian Bassermann
- Department of Medicine III, Hematology and Internal Oncology, TUM School of Medicine Technical University of Munich Munich Germany
| | - Martin Hildebrandt
- Institute of Clinical Chemistry and Pathobiochemistry TUM School of Medicine Technical University of Munich Munich Germany
- Department of Transfusion Medicine, Cellular Therapy and Hemostaseology University Hospital, LMU Munich Munich Germany
| | - Mareike Verbeek
- Department of Medicine III, Hematology and Internal Oncology, TUM School of Medicine Technical University of Munich Munich Germany
| | - Hendrik Poeck
- Department of Medicine III, Hematology and Internal Oncology, TUM School of Medicine Technical University of Munich Munich Germany
- Department of Internal Medicine III, Hematology and Internal Oncology University Hospital Regensburg Regensburg Germany
| |
Collapse
|
11
|
Cavoto G, Chiarello G, Hildebrandt M, Hofer A, Ieki K, Meucci M, Milana S, Pettinacci V, Renga F, Voena C. A photogrammetric method for target monitoring inside the MEG II detector. Rev Sci Instrum 2021; 92:043707. [PMID: 34243372 DOI: 10.1063/5.0034842] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Accepted: 03/27/2021] [Indexed: 06/13/2023]
Abstract
An automatic target monitoring method based on photographs taken by a CMOS photo-camera has been developed for the MEG II detector. The technique could be adapted for other fixed-target experiments requiring good knowledge of their target position to avoid biases and systematic errors in measuring the trajectories of the outcoming particles. A CMOS-based, high resolution, high radiation tolerant, and high magnetic field resistant photo-camera was mounted inside the MEG II detector at the Paul Scherrer Institute (Switzerland). MEG II is used to search for lepton flavor violation in muon decays. The photogrammetric method's challenges, affecting measurements of low momentum particles' tracks, are the high magnetic field of the spectrometer, high radiation levels, tight space constraints, and the need to limit the material budget in the tracking volume. The camera is focused on the dot pattern drawn on the thin MEG II target, about 1 m away from the detector endcaps where the photo-camera is placed. Target movements and deformations are monitored by comparing images of the dots taken at various times during the measurement. The images are acquired with a Raspberry board and analyzed using custom software. Global alignment to the spectrometer is guaranteed by corner cubes placed on the target support. As a result, the target monitoring fulfills the needs of the experiment.
Collapse
Affiliation(s)
- G Cavoto
- Physics Department, Sapienza Università di Roma, P.le Aldo Moro 2, 00185 Rome, Italy
| | - G Chiarello
- INFN Roma, P.le Aldo Moro 2, 00185 Rome, Italy
| | - M Hildebrandt
- Paul Scherrer Institut, Forschungsstrasse 111, 5232 Villigen, Switzerland
| | - A Hofer
- Paul Scherrer Institut, Forschungsstrasse 111, 5232 Villigen, Switzerland
| | - K Ieki
- ICEPP, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - M Meucci
- Physics Department, Sapienza Università di Roma, P.le Aldo Moro 2, 00185 Rome, Italy
| | - S Milana
- INFN Roma, P.le Aldo Moro 2, 00185 Rome, Italy
| | | | - F Renga
- INFN Roma, P.le Aldo Moro 2, 00185 Rome, Italy
| | - C Voena
- INFN Roma, P.le Aldo Moro 2, 00185 Rome, Italy
| |
Collapse
|
12
|
Spiekermann K, Subklewe M, Hildebrandt M, Humpe A, von Bergwelt-Baildon M. COVID-19 aus Sicht der Hämatologie und Hämostaseologie. Transfusionsmedizin 2021. [PMCID: PMC8043599 DOI: 10.1055/a-1309-7275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Die Infektion mit SARS-CoV-2 führt zu einer Reihe von Pathologien im hämatopoetischen System, die die klinische Symptomatik und die Mortalität erheblich beeinflussen. Auch kommt es durch die Aktivierung des Gerinnungssystems zu einer deutlich erhöhten Inzidenz an Thromboembolien. Der Beitrag stellt Pathomechanismen, relevante diagnostische Parameter und den aktuellen Stand zur passiven Immunisierung durch Rekonvaleszentenplasma vor.
Collapse
Affiliation(s)
- Karsten Spiekermann
- Medizinische Klinik und Poliklinik III des LMU-Klinikums Großhadern, München
| | - Marion Subklewe
- Medizinische Klinik und Poliklinik III des LMU-Klinikums Großhadern, München
| | - Martin Hildebrandt
- Abteilung für Transfusionsmedizin, Zelltherapeutika und Hämostaseologie des LMU-Klinikums Großhadern, München
| | - Andreas Humpe
- Abteilung für Transfusionsmedizin, Zelltherapeutika und Hämostaseologie des LMU-Klinikums Großhadern, München
| | | |
Collapse
|
13
|
Antognini A, Ayres NJ, Belosevic I, Bondar V, Eggenberger A, Hildebrandt M, Iwai R, Kaplan DM, Khaw KS, Kirch K, Knecht A, Papa A, Petitjean C, Phillips TJ, Piegsa FM, Ritjoho N, Stoykov A, Taqqu D, Wichmann G. Demonstration of Muon-Beam Transverse Phase-Space Compression. Phys Rev Lett 2020; 125:164802. [PMID: 33124843 DOI: 10.1103/physrevlett.125.164802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/05/2020] [Revised: 08/17/2020] [Accepted: 09/15/2020] [Indexed: 06/11/2023]
Abstract
We demonstrate efficient transverse compression of a 12.5 MeV/c muon beam stopped in a helium gas target featuring a vertical density gradient and crossed electric and magnetic fields. The muon stop distribution extending vertically over 14 mm was reduced to a 0.25 mm size (rms) within 3.5 μs. The simulation including cross sections for low-energy μ^{+}-He elastic and charge exchange (μ^{+}↔ muonium) collisions describes the measurements well. By combining the transverse compression stage with a previously demonstrated longitudinal compression stage, we can improve the phase space density of a μ^{+} beam by a factor of 10^{10} with 10^{-3} efficiency.
Collapse
Affiliation(s)
- A Antognini
- Institute for Particle Physics and Astrophysics, ETH Zürich, 8093 Zürich, Switzerland
- Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
| | - N J Ayres
- Institute for Particle Physics and Astrophysics, ETH Zürich, 8093 Zürich, Switzerland
| | - I Belosevic
- Institute for Particle Physics and Astrophysics, ETH Zürich, 8093 Zürich, Switzerland
| | - V Bondar
- Institute for Particle Physics and Astrophysics, ETH Zürich, 8093 Zürich, Switzerland
| | - A Eggenberger
- Institute for Particle Physics and Astrophysics, ETH Zürich, 8093 Zürich, Switzerland
| | - M Hildebrandt
- Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
| | - R Iwai
- Institute for Particle Physics and Astrophysics, ETH Zürich, 8093 Zürich, Switzerland
| | - D M Kaplan
- Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - K S Khaw
- Institute for Particle Physics and Astrophysics, ETH Zürich, 8093 Zürich, Switzerland
| | - K Kirch
- Institute for Particle Physics and Astrophysics, ETH Zürich, 8093 Zürich, Switzerland
- Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
| | - A Knecht
- Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
| | - A Papa
- Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
- Dipartimento di Fisica, Università di Pisa and INFN sez. Pisa, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - C Petitjean
- Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
| | - T J Phillips
- Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - F M Piegsa
- Institute for Particle Physics and Astrophysics, ETH Zürich, 8093 Zürich, Switzerland
| | - N Ritjoho
- Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
| | - A Stoykov
- Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
| | - D Taqqu
- Institute for Particle Physics and Astrophysics, ETH Zürich, 8093 Zürich, Switzerland
| | - G Wichmann
- Institute for Particle Physics and Astrophysics, ETH Zürich, 8093 Zürich, Switzerland
| |
Collapse
|
14
|
Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, Blankenstein C, Hildebrandt M, Offner R, Ahrens N, Kokowski K, Hautmann M, Rödel C, Fietkau R, Lubgan D, Huber R, Hautmann H, Duell T, Molls M, Specht H, Haller B, Devecka M, Sauter A, Combs SE. Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. Clin Cancer Res 2020; 26:5368-5379. [PMID: 32873573 DOI: 10.1158/1078-0432.ccr-20-1141] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 05/15/2020] [Accepted: 07/21/2020] [Indexed: 11/16/2022]
Abstract
PURPOSE Non-small cell lung cancer (NSCLC) is a fatal disease with poor prognosis. A membrane-bound form of Hsp70 (mHsp70) which is selectively expressed on high-risk tumors serves as a target for mHsp70-targeting natural killer (NK) cells. Patients with advanced mHsp70-positive NSCLC may therefore benefit from a therapeutic intervention involving mHsp70-targeting NK cells. The randomized phase II clinical trial (EudraCT2008-002130-30) explores tolerability and efficacy of ex vivo-activated NK cells in patients with NSCLC after radiochemotherapy (RCT). PATIENTS AND METHODS Patients with unresectable, mHsp70-positive NSCLC (stage IIIa/b) received 4 cycles of autologous NK cells activated ex vivo with TKD/IL2 [interventional arm (INT)] after RCT (60-70 Gy, platinum-based chemotherapy) or RCT alone [control arm (CTRL)]. The primary objective was progression-free survival (PFS), and secondary objectives were the assessment of quality of life (QoL, QLQ-LC13), toxicity, and immunobiological responses. RESULTS The NK-cell therapy after RCT was well tolerated, and no differences in QoL parameters between the two study arms were detected. Estimated 1-year probabilities for PFS were 67% [95% confidence interval (CI), 19%-90%] for the INT arm and 33% (95% CI, 5%-68%) for the CTRL arm (P = 0.36, 1-sided log-rank test). Clinical responses in the INT group were associated with an increase in the prevalence of activated NK cells in their peripheral blood. CONCLUSIONS Ex vivo TKD/IL2-activated, autologous NK cells are well tolerated and deliver positive clinical responses in patients with advanced NSCLC after RCT.
Collapse
Affiliation(s)
- Gabriele Multhoff
- Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), Munich, Germany. .,Radiation Immuno-Oncology, Center for Translational Cancer Research TUM (TranslaTUM), Munich, Germany
| | - Sophie Seier
- Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), Munich, Germany
| | - Stefan Stangl
- Radiation Immuno-Oncology, Center for Translational Cancer Research TUM (TranslaTUM), Munich, Germany
| | - Wolfgang Sievert
- Radiation Immuno-Oncology, Center for Translational Cancer Research TUM (TranslaTUM), Munich, Germany
| | - Maxim Shevtsov
- Radiation Immuno-Oncology, Center for Translational Cancer Research TUM (TranslaTUM), Munich, Germany.,Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russia
| | - Caroline Werner
- Radiation Immuno-Oncology, Center for Translational Cancer Research TUM (TranslaTUM), Munich, Germany
| | - A Graham Pockley
- John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom; and multimmune GmbH, Munich, Germany
| | | | | | - Robert Offner
- Department of Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany
| | - Norbert Ahrens
- Department of Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany
| | - Konrad Kokowski
- Pneumology and Pneumologic Oncology, Klinikum Bogenhausen, Munich, Germany
| | - Matthias Hautmann
- Department of Radiation Oncology, University Hospital Regensburg, Regensburg, Germany
| | - Claus Rödel
- Department of Radiotherapy and Oncology, Goethe University Frankfurt, Frankfurt, Germany
| | - Rainer Fietkau
- Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Dorota Lubgan
- Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Rudolf Huber
- Division of Respiratory Medicine and Thoracic Oncology Centre Munich and Thoracic Oncology Centre Munich, University München, LMU, Munich, Germany
| | - Hubert Hautmann
- Pneumology Group Med I, Klinikum rechts der Isar, TUM, Munich, Germany
| | - Thomas Duell
- Asklepios Lung Hospital München-Gauting, Thoracal Pneumology, LMU, Munich, Germany
| | - Michael Molls
- Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), Munich, Germany
| | - Hanno Specht
- Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), Munich, Germany
| | - Bernhard Haller
- Institute of Medical Informatics, Statistics and Epidemiology, TUM, Munich, Germany
| | - Michal Devecka
- Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), Munich, Germany
| | | | - Stephanie E Combs
- Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), Munich, Germany.,Institute of Radiation Medicine (IRM), Helmholtz Zentrum München (HMGU), Neuherberg, Germany.,Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany
| |
Collapse
|
15
|
Multhoff G, Combs SE, Seier S, Stangl S, Sievert W, Shevtsov M, Blankenstein C, Hildebrandt M, Kokowski K, Hautmann M, Hautmann H, Roedel C, Fietkau R, Huber RM, Haller B, Ertl C, Devecka M, Offner R, Ahrens N. Abstract LB-076: Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy - results of a randomized phase II clinical trial (NSCLC-TKD/IL-2) (Eudra-CT Number 2008-002130-30). Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-lb-076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Membrane-bound heat shock protein 70 (mHsp70) is indicative for high-risk tumors with negative prognosis but also serves as a target for NK cells that are stimulated with Hsp70 peptide TKD and low dose IL-2 (TKD/IL-2). Herein, the efficacy of ex vivo TKD/IL-2 activated, autologous NK cells was tested in a randomized, investigator initiated phase II clinical trial in patients with mHsp70 positive advanced stage NSCLC after radiochemotherapy (RCT, 60-70 Gy, platinum-based chemotherapy). The interventional (INT) group received 4 cycles TKD/IL-2 activated, autologous NK cells every 2-6 weeks subsequent to standard RCT and the control (CTRL) group received best supportive care. The primary objective of the study was to examine whether the adjuvant treatment of NSCLC patients with TKD/IL-2 activated NK cells is feasible and effective with respect to progression-free survival (PFS). Secondary objectives were the assessment of treatment and biological responses, toxicity, quality-of-life (QoL, QLQ-LC13). Eight patients were randomized into the INT and eight into the CTRL arm. None of the patients died between randomization and final tumor assessment 18 months after randomization. In the INT group one patient had complete response (CR), one patient partial response (PR), two patients stable disease (SD) and one patient progressive disease (PD) at the last documented visit, whereas in the CTRL group only 2 patients showed clinical responses (PR, SD) and five patients had PD. The clinical response of patients in the INT group appeared to be mediated by activated NK cells whereas in the CTRL group by CD8+ T cells. The NK cell therapy after RCT was well tolerated, no differences in QoL were observed between both study groups.
Citation Format: Gabriele Multhoff, Stephanie E. Combs, Sophie Seier, Stefan Stangl, Wolfgang Sievert, Maxim Shevtsov, Christiane Blankenstein, Martin Hildebrandt, Konrad Kokowski, Matthias Hautmann, Hubert Hautmann, Claus Roedel, Rainer Fietkau, Rudolf M. Huber, Bernhard Haller, Christina Ertl, Michal Devecka, Robert Offner, Norbert Ahrens. Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy - results of a randomized phase II clinical trial (NSCLC-TKD/IL-2) (Eudra-CT Number 2008-002130-30) [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr LB-076.
Collapse
Affiliation(s)
| | | | - Sophie Seier
- 1Klinikum rechts der Isar TU Munich, Munich, Germany
| | - Stefan Stangl
- 1Klinikum rechts der Isar TU Munich, Munich, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Robert Offner
- 3Universitätsklinikum Regensburg, Regensburg, Germany
| | | |
Collapse
|
16
|
Spiekermann K, Subklewe M, Hildebrandt M, Humpe A, von Bergwelt-Baildon M. [COVID-19 from the Perspective of Haematology and Haemostaseology]. Dtsch Med Wochenschr 2020; 145:1044-1050. [PMID: 32731277 DOI: 10.1055/a-1164-4191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Infection with SARS-COV-2 leads to a number of pathologies in the hematopoetic system that have significant impact on clinical symptoms and mortality. There are 3 stages of infection: (1) early upper respiratory tract infection with fever and lymphopenia (2) pulmonary phase and (3) hyperinflammatory phase with the clinical signs of organ failure such as ARDS/shock. Hyperinflammation, which is triggered by activation of T cells and monocytes/macrophages, is essential for organ pathologies. Interferon IFN-ɣ, tumor necrosis factor (TNF)-α, IL-10 and interleukin-6 (IL-6) play important roles as mediators of inflammation. In analogy to the cytokine release syndrome (CRS) after CAR-T cell therapy, the therapeutic activity of the IL-6 receptor antibody tocilizumab is investigated in clinical studies.The coagulation system is activated during the inflammatory phase of COVID infection, most likely on the pathophysiological basis of immune thrombosis. Clinically, there is a significantly increased incidence of venous (especially pulmonary artery embolism), but also arterial thromboembolism (TE). In laboratory chemistry, the D-dimer, fibrinogen but also vWF and FVIII are significantly increased. Guidelines for the prophylaxis and therapy of COVID-associated coagulopathy have been developed. Analogous to other viral infections, there are approaches to passive immunization using convalescent plasma. Its administration has shown promising activity in first uncontrolled case series and is currently being examined in clinical studies worldwide for its therapeutic activity.
Collapse
|
17
|
Aguzzi J, Flexas MM, Flögel S, Lo Iacono C, Tangherlini M, Costa C, Marini S, Bahamon N, Martini S, Fanelli E, Danovaro R, Stefanni S, Thomsen L, Riccobene G, Hildebrandt M, Masmitja I, Del Rio J, Clark EB, Branch A, Weiss P, Klesh AT, Schodlok MP. Exo-Ocean Exploration with Deep-Sea Sensor and Platform Technologies. Astrobiology 2020; 20:897-915. [PMID: 32267735 DOI: 10.1089/ast.2019.2129] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
One of Saturn's largest moons, Enceladus, possesses a vast extraterrestrial ocean (i.e., exo-ocean) that is increasingly becoming the hotspot of future research initiatives dedicated to the exploration of putative life. Here, a new bio-exploration concept design for Enceladus' exo-ocean is proposed, focusing on the potential presence of organisms across a wide range of sizes (i.e., from uni- to multicellular and animal-like), according to state-of-the-art sensor and robotic platform technologies used in terrestrial deep-sea research. In particular, we focus on combined direct and indirect life-detection capabilities, based on optoacoustic imaging and passive acoustics, as well as molecular approaches. Such biologically oriented sampling can be accompanied by concomitant geochemical and oceanographic measurements to provide data relevant to exo-ocean exploration and understanding. Finally, we describe how this multidisciplinary monitoring approach is currently enabled in terrestrial oceans through cabled (fixed) observatories and their related mobile multiparametric platforms (i.e., Autonomous Underwater and Remotely Operated Vehicles, as well as crawlers, rovers, and biomimetic robots) and how their modified design can be used for exo-ocean exploration.
Collapse
Affiliation(s)
- J Aguzzi
- Instituto de Ciencias del Mar (ICM-CSIC), Barcelona, Spain
- Stazione Zoologica Anton Dohrn, Naples, Italy
| | - M M Flexas
- California Institute of Technology, Pasadena, California, USA
| | - S Flögel
- GEOMAR Helmholtz Centre for Ocean Research Kiel, Kiel, Germany
| | - C Lo Iacono
- Instituto de Ciencias del Mar (ICM-CSIC), Barcelona, Spain
- National Oceanographic Center (NOC), University of Southampton, Southampton, United Kingdom
| | | | - C Costa
- Consiglio per la ricerca in agricoltura e l'analisi dell'economia agraria (CREA)-Centro di ricerca Ingegneria e Trasformazioni agroalimentari - Monterotondo, Rome, Italy
| | - S Marini
- Stazione Zoologica Anton Dohrn, Naples, Italy
- National Research Council of Italy (CNR), Institute of Marine Sciences, La Spezia, Italy
| | - N Bahamon
- Instituto de Ciencias del Mar (ICM-CSIC), Barcelona, Spain
- Centro de Estudios Avanzados de Blanes (CEAB-CSIC), Blanes, Spain
| | - S Martini
- Sorbonne Université, CNRS, Laboratoire d'Océanographie de Villefranche, Villefranche-sur-mer, France
| | - E Fanelli
- Stazione Zoologica Anton Dohrn, Naples, Italy
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - R Danovaro
- Stazione Zoologica Anton Dohrn, Naples, Italy
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - S Stefanni
- Stazione Zoologica Anton Dohrn, Naples, Italy
| | | | - G Riccobene
- Istituto Nazionale di Fisica Nucleare (INFN), Laboratori Nazionali del Sud, Catania, Italy
| | - M Hildebrandt
- German Research Center for Artificial Intelligence (DFKI), Bremen, Germany
| | - I Masmitja
- SARTI, Universitat Politècnica de Catalunya (UPC), Barcelona, Spain
| | - J Del Rio
- SARTI, Universitat Politècnica de Catalunya (UPC), Barcelona, Spain
| | - E B Clark
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, California, USA
| | - A Branch
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, California, USA
| | | | - A T Klesh
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, California, USA
| | - M P Schodlok
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, California, USA
| |
Collapse
|
18
|
Hildebrandt M. Horses for courses: an approach to the qualification of clinical trial sites and investigators in ATMPs. Drug Discov Today 2020; 25:265-268. [DOI: 10.1016/j.drudis.2019.10.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2019] [Revised: 10/01/2019] [Accepted: 10/07/2019] [Indexed: 12/17/2022]
|
19
|
Faist B, Schlott F, Stemberger C, Dennehy KM, Krackhardt A, Verbeek M, Grigoleit GU, Schiemann M, Hoffmann D, Dick A, Martin K, Hildebrandt M, Busch DH, Neuenhahn M. Targeted in-vitro-stimulation reveals highly proliferative multi-virus-specific human central memory T cells as candidates for prophylactic T cell therapy. PLoS One 2019; 14:e0223258. [PMID: 31568490 PMCID: PMC6768573 DOI: 10.1371/journal.pone.0223258] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Accepted: 09/17/2019] [Indexed: 01/16/2023] Open
Abstract
Adoptive T cell therapy (ACT) has become a treatment option for viral reactivations in patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). Animal models have shown that pathogen-specific central memory T cells (TCM) are protective even at low numbers and show long-term survival, extensive proliferation and high plasticity after adoptive transfer. Concomitantly, our own recent clinical data demonstrate that minimal doses of purified (not in-vitro- expanded) human CMV epitope-specific T cells can be sufficient to clear viremia. However, it remains to be determined if human virus-specific TCM show the same promising features for ACT as their murine counterparts. Using a peptide specific proliferation assay (PSPA) we studied the human Adenovirus- (AdV), Cytomegalovirus- (CMV) and Epstein-Barr virus- (EBV) specific TCM repertoires and determined their functional and proliferative capacities in vitro. TCM products were generated from buffy coats, as well as from non-mobilized and mobilized apheresis products either by flow cytometry-based cell sorting or magnetic cell enrichment using reversible Fab-Streptamers. Adjusted to virus serology and human leukocyte antigen (HLA)-typing, donor samples were analyzed with MHC multimer- and intracellular cytokine staining (ICS) before and after PSPA. TCM cultures showed strong proliferation of a plethora of functional virus-specific T cells. Using PSPA, we could unveil tiniest virus epitope-specific TCM populations, which had remained undetectable in conventional ex-vivo-staining. Furthermore, we could confirm these characteristics for mobilized apheresis- and GMP-grade Fab-Streptamer-purified TCM products. Consequently, we conclude that TCM bare high potential for prophylactic low-dose ACT. In addition, use of Fab-Streptamer-purified TCM allows circumventing regulatory restrictions typically found in conventional ACT product generation. These GMP-compatible TCM can now be used as a broad-spectrum antiviral T cell prophylaxis in alloHSCT patients and PSPA is going to be an indispensable tool for advanced TCM characterization during concomitant immune monitoring.
Collapse
Affiliation(s)
- Benjamin Faist
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany
- German Center for Infection Research (DZIF), partner site Munich, Munich, Germany
| | - Fabian Schlott
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany
- German Center for Infection Research (DZIF), partner site Munich, Munich, Germany
| | | | - Kevin M. Dennehy
- German Center for Infection Research (DZIF), partner site Tübingen, Tübingen, Germany
- Institute for Medical Virology, University Hospital Tübingen, Tübingen, Germany
| | - Angela Krackhardt
- Department of Medicine III, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
| | - Mareike Verbeek
- Department of Medicine III, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
| | - Götz U. Grigoleit
- Department of Internal Medicine II, University of Würzburg, Wuerzburg, Germany
| | - Matthias Schiemann
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany
| | - Dieter Hoffmann
- German Center for Infection Research (DZIF), partner site Munich, Munich, Germany
- Institute for Virology, Technische Universität München, Munich, Germany
| | - Andrea Dick
- Department of Transfusion Medicine and Haemostaseology, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Klaus Martin
- Institute of Anaesthesiology, Deutsches Herzzentrum München, Klinik an der Technischen Universität München, Munich, Germany
| | - Martin Hildebrandt
- TUM Cells Interdisciplinary Center for Cellular Therapies, Munich, Germany
| | - Dirk H. Busch
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany
- German Center for Infection Research (DZIF), partner site Munich, Munich, Germany
| | - Michael Neuenhahn
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany
- German Center for Infection Research (DZIF), partner site Munich, Munich, Germany
- TUM Cells Interdisciplinary Center for Cellular Therapies, Munich, Germany
- * E-mail:
| |
Collapse
|
20
|
Multhoff G, Kokowski K, Hildebrandt M, Vaupel P, Stangl S. Abstract LB-016: Radiochemotherapy combined with NK cells followed by a second-line PD-1 inhibition in a patients with NSCLC stage IIIb induces long-term tumor control. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-lb-016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Advanced stage NSCLC is a fatal disease with poor prognosis. Following radiochemotherapy (RCT) tumor progression occurs after 5.6 months in stage III NSCLC patients. We identified membrane heat shock protein 70 (mHsp70) as a biomarker for high-risk NSCLC. Furthermore, mHsp70 serves as a tumor-specific target for NK cells that had been stimulated with Hsp70-peptide (TKD) and IL-2. In this study, a patient with mHsp70 positive inoperable NSCLC (cT4, cN3, cM0, stage IIIb) was treated for the first time with a combined therapy consisting of RCT (64.8 Gy), 4 cycles of mHsp70-targeting, autologous NK cells and PD-1 antibody, as a second-line therapy.
Adoptive transfer of ex vivo Hsp70-activated NK cells after RCT combined with PD-1 inhibition was well tolerated and resulted in a superior OS. No viable tumor cells, but a massive immune cell infiltration of T and NK cells in fibrotic tissue were detected after therapy. Neither tumor progression nor distant metastases were detectable by CT-scanning 35 months after diagnosis. Therapy response was associated with significantly increased CD3-/NKG2D+/CD94+ NK cell counts, elevated CD8+ to CD4+ T cell, CD3-/CD56bright to CD3-/CD56dim NK cell ratios, and significantly reduced regulatory T cells (Tregs) in the peripheral blood. In summary, a combined immunotherapy consisting of RCT, mHsp70-targeting NK cells and PD-1 antibody inhibition is well tolerated, induces anti-tumor immune responses and results in long-term tumor control in a patient with advanced NSCLC.
Citation Format: Gabriele Multhoff, Konrad Kokowski, Martin Hildebrandt, Peter Vaupel, Stefan Stangl. Radiochemotherapy combined with NK cells followed by a second-line PD-1 inhibition in a patients with NSCLC stage IIIb induces long-term tumor control [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-016.
Collapse
Affiliation(s)
| | | | | | - Peter Vaupel
- 1Klinikum rechts der Isar TU Munich, Munich, Germany
| | - Stefan Stangl
- 1Klinikum rechts der Isar TU Munich, Munich, Germany
| |
Collapse
|
21
|
Hildebrandt M. Considerations regarding the qualification of clinical trial sites and investigators in clinical trials with ATMPs. Cytotherapy 2019. [DOI: 10.1016/j.jcyt.2019.03.394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Segschneider V, Pelzel J, Hildebrandt M, Andrade A. Validation of computerized systems– a risk based modular approach. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
23
|
Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, Eichmüller SB, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels WS, Schüssler-Lenz M. Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach. Cancer Immunol Immunother 2018; 67:513-523. [PMID: 29380009 PMCID: PMC11028374 DOI: 10.1007/s00262-018-2119-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2017] [Accepted: 01/20/2018] [Indexed: 12/17/2022]
Abstract
Adoptive transfer of T cells genetically modified by TCRs or CARs represents a highly attractive novel therapeutic strategy to treat malignant diseases. Various approaches for the development of such gene therapy medicinal products (GTMPs) have been initiated by scientists in recent years. To date, however, the number of clinical trials commenced in Germany and Europe is still low. Several hurdles may contribute to the delay in clinical translation of these therapeutic innovations including the significant complexity of manufacture and non-clinical testing of these novel medicinal products, the limited knowledge about the intricate regulatory requirements of the academic developers as well as limitations of funds for clinical testing. A suitable good manufacturing practice (GMP) environment is a key prerequisite and platform for the development, validation, and manufacture of such cell-based therapies, but may also represent a bottleneck for clinical translation. The German Cancer Consortium (DKTK) and the Paul-Ehrlich-Institut (PEI) have initiated joint efforts of researchers and regulators to facilitate and advance early phase, academia-driven clinical trials. Starting with a workshop held in 2016, stakeholders from academia and regulatory authorities in Germany have entered into continuing discussions on a diversity of scientific, manufacturing, and regulatory aspects, as well as the benefits and risks of clinical application of CAR/TCR-based cell therapies. This review summarizes the current state of discussions of this cooperative approach providing a basis for further policy-making and suitable modification of processes.
Collapse
Affiliation(s)
- Angela M Krackhardt
- Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie, Klinikum rechts der Isar, TU München, TUM School of Medicine, Munich, Germany.
- DKTK-Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium) and DKFZ-Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany.
| | - Brigitte Anliker
- Paul-Ehrlich-Institut (PEI, German Federal Institute for Vaccines and Biomedicines), Langen, Germany
| | - Martin Hildebrandt
- DKTK-Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium) and DKFZ-Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany
- TUMCells (Interdisciplinary Center for Cellular Therapies), TUM School of Medicine, Munich, Germany
| | - Michael Bachmann
- DKTK-Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium) and DKFZ-Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany
- Helmholtz Zentrum Dresden Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Radio and Tumorimmunology, Dresden, Germany
- Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg and Dresden, Germany
| | - Stefan B Eichmüller
- DKTK-Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium) and DKFZ-Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany
- Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg and Dresden, Germany
- GMP and T Cell Therapy Unit, DKFZ-Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany
| | - Dirk M Nettelbeck
- DKTK-Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium) and DKFZ-Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany
| | - Matthias Renner
- Paul-Ehrlich-Institut (PEI, German Federal Institute for Vaccines and Biomedicines), Langen, Germany
| | - Lutz Uharek
- DKTK-Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium) and DKFZ-Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany
- Stem Cell Facility, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Gerald Willimsky
- DKTK-Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium) and DKFZ-Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany
- Institute of Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Michael Schmitt
- DKTK-Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium) and DKFZ-Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany
- Department of Internal Medicine V, GMP Core Facility, Heidelberg University Hospital, Heidelberg, Germany
| | - Winfried S Wels
- DKTK-Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium) and DKFZ-Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - Martina Schüssler-Lenz
- Paul-Ehrlich-Institut (PEI, German Federal Institute for Vaccines and Biomedicines), Langen, Germany
| |
Collapse
|
24
|
Abstract
ZusammenfassungMit dem Einsatz von radiomarkierten Antisense-Oligonukleotiden als Tracer in der Nuklearmedizin eröffnet sich eine vielversprechende Perspektive, neue Wege in der bildgebenden Diagnostik zu beschreiten. Vor allem in der Tumordiagnostik scheint eine quantitative Akkumulation von Antisense-Proben, welche gegen abundant exprimierte Onkogen-mRNAs gerichtet sind, vorstellbar. Dazu ist allerdings noch eine Optimierung folgender Parameter erforderlich: (i) eine schnelle und effiziente Radiomarkierung von Oligonukleotiden mit in der Nuklearmedizin gebräuchlichen Isotopen, (ü) eine rasche Penetration der Nukleinsäure ins Zielgewebe, (iii) eine zügige Internalisierung des Tracers in die Tumorzellen, (iv) eine hohe Spezifität der Hybridbildung mit der Target-mRNA, und (v) eine hohe Stabilität des gebildeten Hybrids gegenüber intrazellulären Nukleasen.
Collapse
|
25
|
Slobodianski A, Hildebrandt M, Machens H. Safety and Manufacturing Aspects of Cell-Based Therapies. Cytotherapy 2016. [DOI: 10.1016/j.jcyt.2016.03.285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
de Wilde S, Guchelaar HJ, Herberts C, Lowdell M, Hildebrandt M, Zandvliet M, Meij P. Development of cell therapy medicinal products by academic institutes. Drug Discov Today 2016; 21:1206-12. [PMID: 27117349 DOI: 10.1016/j.drudis.2016.04.016] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Revised: 03/30/2016] [Accepted: 04/18/2016] [Indexed: 02/01/2023]
Abstract
In the rapidly evolving fields of cellular immunotherapy, gene therapy and regenerative medicine, a wide range of promising cell therapy medicinal products are in clinical development. Most products originate from academic research and are explored in early exploratory clinical trials. However, the success rate toward approval for regular patient care is disappointingly low. In this paper, we define strengths and hurdles applying to the development of cell therapy medicinal products in academic institutes, and analyze why only a few promising cell therapies have reached late-stage clinical development. Subsequently, we provide recommendations to stakeholders involved in development of cell therapies to exploit their potential clinical benefit.
Collapse
Affiliation(s)
- Sofieke de Wilde
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
| | - Henk-Jan Guchelaar
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
| | - Carla Herberts
- Pharmacotherapeutic Group 3, Medicines Evaluation Board (MEB), Utrecht, The Netherlands
| | - Mark Lowdell
- Department of Hematology, Royal Free Hospital & University College London, UK
| | - Martin Hildebrandt
- Technical University Munich, Faculty of Medicine, TUM Cells Interdisciplinary Center for Cellular Therapies, Munich, Germany
| | - Maarten Zandvliet
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
| | - Pauline Meij
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
27
|
Antognini A, Schuhmann K, Amaro FD, Amaro P, Abdou-Ahmed M, Biraben F, Chen TL, Covita DS, Dax AJ, Diepold M, Fernandes LMP, Franke B, Galtier S, Gouvea AL, Götzfried J, Graf T, Hänsch TW, Hildebrandt M, Indelicato P, Julien L, Kirch K, Knecht A, Kottmann F, Krauth JJ, Liu YW, Machado J, Monteiro CMB, Mulhauser F, Nez F, Santos JP, dos Santos JMF, Szabo CI, Taqqu D, Veloso JFCA, Voss A, Weichelt B, Pohl R. Experiments towards resolving the proton charge radius puzzle. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611301006] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Pargac N, Kahleyss S, Knötzsch A, Hildebrandt M. Gefahr beim Stillen: 8 Monate alter gestillter Säugling mit neurodegenerativen ZNS-Veränderungen und Hypogammaglobulinämie durch Vitamin B12-Mangel. Z Geburtshilfe Neonatol 2015. [DOI: 10.1055/s-0035-1566519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
29
|
Pauli G, Aepfelbacher M, Bauerfeind U, Blümel J, Burger R, Gärtner B, Gröner A, Gürtler L, Heiden M, Hildebrandt M, Jansen B, Offergeld R, Schlenkrich U, Schottstedt V, Seitz R, Strobel J, Willkommen H, Baylis SA. Hepatitis E Virus. Transfus Med Hemother 2015; 42:247-65. [PMID: 26557817 DOI: 10.1159/000431191] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Accepted: 02/10/2015] [Indexed: 12/12/2022] Open
|
30
|
Hildebrandt M, Fankhauser G, Meichtry A, Luomajoki H. Correlation between lumbar dysfunction and fat infiltration in lumbar multifidus muscles in patients with low back pain. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.3379] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
31
|
Chabannon C, Hildebrandt M, Scheding S, Humpe A, Lowdell M, Slaper-Cortenbach I. Regulation of advanced therapy medicinal products will affect the practice of haematopoietic SCT in the near future: a perspective from the EBMT cell-processing committee. Bone Marrow Transplant 2014; 50:321-3. [DOI: 10.1038/bmt.2014.271] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
32
|
Cuende N, Boniface C, Bravery C, Forte M, Giordano R, Hildebrandt M, Izeta A, Dominici M. The puzzling situation of hospital exemption for advanced therapy medicinal products in Europe and stakeholders' concerns. Cytotherapy 2014; 16:1597-600. [DOI: 10.1016/j.jcyt.2014.08.007] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Accepted: 08/13/2014] [Indexed: 10/24/2022]
|
33
|
Ammar C, Frey K, Bauer J, Melzig C, Chiblak S, Hildebrandt M, Unholtz D, Kurz C, Brons S, Debus J, Abdollahi A, Parodi K. Comparing the biological washout of β+-activity induced in mice brain after 12C-ion and proton irradiation. Phys Med Biol 2014; 59:7229-44. [PMID: 25383509 DOI: 10.1088/0031-9155/59/23/7229] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
In clinical ion beam therapy, protons as well as heavier ions such as carbon are used for treatment. For protons, β(+)-emitters are only induced by fragmentation reactions in the target (target fragmentation), whereas for heavy ions, they are additionally induced by fragmentations of the projectile (further referred to as autoactivation). An approach utilizing these processes for treatment verification, by comparing measured Positron Emission Tomography (PET) data to predictions from Monte Carlo simulations, has already been clinically implemented. For an accurate simulation, it is important to consider the biological washout of β(+)-emitters due to vital functions. To date, mathematical expressions for washout have mainly been determined by using radioactive beams of (10)C- and (11)C-ions, both β(+)-emitters, to enhance the counting statistics in the irradiated area. Still, the question of how the choice of projectile (autoactivating or non-autoactivating) influences the washout coefficients, has not been addressed. In this context, an experiment was carried out at the Heidelberg Ion Beam Therapy Center with the purpose of directly comparing irradiation-induced biological washout coefficients in mice for protons and (12)C-ions. To this aim, mice were irradiated in the brain region with protons and (12)C-ions and measured after irradiation with a PET/CT scanner (Siemens Biograph mCT). After an appropriate waiting time, the mice were sacrificed, then irradiated and measured again under similar conditions. The resulting data were processed and fitted numerically to deduce the main washout parameters. Despite the very low PET counting statistics, a consistent difference could be identified between (12)C-ion and proton irradiated mice, with the (12)C data being described best by a two component fit with a combined medium and slow washout fraction of 0.50 ± 0.05 and the proton mice data being described best by a one component fit with only one (slow) washout fraction of 0.73 ± 0.06.
Collapse
Affiliation(s)
- C Ammar
- Ludwig-Maximilians University, Faculty of Physics, Department of Medical Physics, Am Coulombwall 1, 85748 Garching b. Munich, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Pearce KF, Hildebrandt M, Greinix H, Scheding S, Koehl U, Worel N, Apperley J, Edinger M, Hauser A, Mischak-Weissinger E, Dickinson AM, Lowdell MW. Regulation of advanced therapy medicinal products in Europe and the role of academia. Cytotherapy 2014; 16:289-97. [DOI: 10.1016/j.jcyt.2013.08.003] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2013] [Revised: 08/01/2013] [Accepted: 08/10/2013] [Indexed: 10/26/2022]
|
35
|
Pauli G, Bauerfeind U, Blümel J, Burger R, Drosten C, Gröner A, Gürtler L, Heiden M, Hildebrandt M, Jansen B, Offergeld R, Seitz R, Schlenkrich U, Schottstedt V, Strobel J, Willkommen H. Usutu virus. Transfus Med Hemother 2014; 41:73-82. [PMID: 24659950 PMCID: PMC3949607 DOI: 10.1159/000357106] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2013] [Accepted: 05/09/2013] [Indexed: 12/28/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Rainer Seitz
- Arbeitskreis Blut, Untergruppe «Bewertung Blutassoziierter Krankheitserreger»
| | | | | | | | | |
Collapse
|
36
|
Gürtler L, Bauerfeind U, Blümel J, Burger R, Drosten C, Gröner A, Heiden M, Hildebrandt M, Jansen B, Offergeld R, Pauli G, Seitz R, Schlenkrich U, Schottstedt V, Strobel J, Willkommen H. Coxiella burnetii - Pathogenic Agent of Q (Query) Fever. Transfus Med Hemother 2014; 41:60-72. [PMID: 24659949 PMCID: PMC3949614 DOI: 10.1159/000357107] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2013] [Accepted: 05/09/2013] [Indexed: 12/25/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Rainer Seitz
- Arbeitskreis Blut, Untergruppe «Bewertung Blutassoziierter Krankheitserreger»
| | | | | | | | | |
Collapse
|
37
|
Pauli G, Bauerfeind U, Blümel J, Burger R, Drosten C, Gröner A, Gürtler L, Heiden M, Hildebrandt M, Jansen B, Montag-Lessing T, Offergeld R, Seitz R, Schlenkrich U, Schottstedt V, Strobel J, Willkommen H. West nile virus. Transfus Med Hemother 2013; 40:265-84. [PMID: 24179475 PMCID: PMC3776406 DOI: 10.1159/000353698] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2012] [Accepted: 07/15/2012] [Indexed: 12/12/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Rainer Seitz
- Arbeitskreis Blut, Untergruppe «Bewertung Blutassoziierter Krankheitserreger»
| | | | | | | | | |
Collapse
|
38
|
Bauer J, Hildebrandt M, Unholtz D, Kurz C, Parodi K. TH-C-144-12: On the Modelling of Facility-Specific PET Imaging for Proton Treatment Verification: Experimental Validation and Inter-Facility Comparison. Med Phys 2013. [DOI: 10.1118/1.4815806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
39
|
Adam J, Bai X, Baldini AM, Baracchini E, Bemporad C, Boca G, Cattaneo PW, Cavoto G, Cei F, Cerri C, de Bari A, De Gerone M, Doke T, Dussoni S, Egger J, Fujii Y, Galli L, Gatti F, Golden B, Grassi M, Graziosi A, Grigoriev DN, Haruyama T, Hildebrandt M, Hisamatsu Y, Ignatov F, Iwamoto T, Kaneko D, Kettle PR, Khazin BI, Khomotov N, Kiselev O, Korenchenko A, Kravchuk N, Lim G, Maki A, Mihara S, Molzon W, Mori T, Mzavia D, Nardò R, Natori H, Nicolò D, Nishiguchi H, Nishimura Y, Ootani W, Panareo M, Papa A, Piredda G, Popov A, Renga F, Ripiccini E, Ritt S, Rossella M, Sawada R, Sergiampietri F, Signorelli G, Suzuki S, Tenchini F, Topchyan C, Uchiyama Y, Voena C, Xiao F, Yamada S, Yamamoto A, Yamashita S, You Z, Yudin YV, Zanello D. New constraint on the existence of the μ+ → e+ γ decay. Phys Rev Lett 2013; 110:201801. [PMID: 25167396 DOI: 10.1103/physrevlett.110.201801] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Indexed: 06/03/2023]
Abstract
The analysis of a combined data set, totaling 3.6 × 10(14) stopped muons on target, in the search for the lepton flavor violating decay μ(+) → e(+)γ is presented. The data collected by the MEG experiment at the Paul Scherrer Institut show no excess of events compared to background expectations and yield a new upper limit on the branching ratio of this decay of 5.7 × 10(-13) (90% confidence level). This represents a four times more stringent limit than the previous world best limit set by MEG.
Collapse
Affiliation(s)
- J Adam
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland and Swiss Federal Institute of Technology ETH, CH-8093 Zürich, Switzerland
| | - X Bai
- ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - A M Baldini
- INFN Sezione di Pisa, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - E Baracchini
- ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan and KEK, High Energy Accelerator Research Organization 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan and University of California, Irvine, California 92697, USA
| | - C Bemporad
- INFN Sezione di Pisa, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy and Dipartimento di Fisica, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - G Boca
- INFN Sezione di Pavia, dell'Università, Via Bassi 6, 27100 Pavia, Italy and Dipartimento di Fisica, dell'Università, Via Bassi 6, 27100 Pavia, Italy
| | - P W Cattaneo
- INFN Sezione di Pavia, dell'Università, Via Bassi 6, 27100 Pavia, Italy
| | - G Cavoto
- INFN Sezione di Roma, dell'Università "Sapienza", Piazzale A. Moro, 00185 Roma, Italy
| | - F Cei
- INFN Sezione di Pisa, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy and Dipartimento di Fisica, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - C Cerri
- INFN Sezione di Pisa, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - A de Bari
- INFN Sezione di Pavia, dell'Università, Via Bassi 6, 27100 Pavia, Italy and Dipartimento di Fisica, dell'Università, Via Bassi 6, 27100 Pavia, Italy
| | - M De Gerone
- INFN Sezione di Genova, dell'Università, Via Dodecaneso 33, 16146 Genova, Italy and Dipartimento di Fisica, dell'Università, Via Dodecaneso 33, 16146 Genova, Italy
| | - T Doke
- Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan
| | - S Dussoni
- INFN Sezione di Pisa, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - J Egger
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland
| | - Y Fujii
- ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - L Galli
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland and INFN Sezione di Pisa, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - F Gatti
- INFN Sezione di Genova, dell'Università, Via Dodecaneso 33, 16146 Genova, Italy and Dipartimento di Fisica, dell'Università, Via Dodecaneso 33, 16146 Genova, Italy
| | - B Golden
- University of California, Irvine, California 92697, USA
| | - M Grassi
- INFN Sezione di Pisa, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - A Graziosi
- INFN Sezione di Roma, dell'Università "Sapienza", Piazzale A. Moro, 00185 Roma, Italy
| | - D N Grigoriev
- Budker Institute of Nuclear Physics, 630090 Novosibirsk, Russia and Novosibirsk State Technical University, 630092 Novosibirsk, Russia
| | - T Haruyama
- KEK, High Energy Accelerator Research Organization 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - M Hildebrandt
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland
| | - Y Hisamatsu
- ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - F Ignatov
- Budker Institute of Nuclear Physics, 630090 Novosibirsk, Russia
| | - T Iwamoto
- ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - D Kaneko
- ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - P-R Kettle
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland
| | - B I Khazin
- Budker Institute of Nuclear Physics, 630090 Novosibirsk, Russia
| | - N Khomotov
- Budker Institute of Nuclear Physics, 630090 Novosibirsk, Russia
| | - O Kiselev
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland
| | - A Korenchenko
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - N Kravchuk
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - G Lim
- University of California, Irvine, California 92697, USA
| | - A Maki
- KEK, High Energy Accelerator Research Organization 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - S Mihara
- KEK, High Energy Accelerator Research Organization 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - W Molzon
- University of California, Irvine, California 92697, USA
| | - T Mori
- ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - D Mzavia
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - R Nardò
- INFN Sezione di Pavia, dell'Università, Via Bassi 6, 27100 Pavia, Italy
| | - H Natori
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland and ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan and KEK, High Energy Accelerator Research Organization 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - D Nicolò
- INFN Sezione di Pisa, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy and Dipartimento di Fisica, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - H Nishiguchi
- KEK, High Energy Accelerator Research Organization 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - Y Nishimura
- ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - W Ootani
- ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - M Panareo
- INFN Sezione di Lecce, dell'Università, Via per Arnesano, 73100 Lecce, Italy and Dipartimento di Fisica, dell'Università, Via per Arnesano, 73100 Lecce, Italy
| | - A Papa
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland
| | - G Piredda
- INFN Sezione di Roma, dell'Università "Sapienza", Piazzale A. Moro, 00185 Roma, Italy
| | - A Popov
- Budker Institute of Nuclear Physics, 630090 Novosibirsk, Russia
| | - F Renga
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland and INFN Sezione di Roma, dell'Università "Sapienza", Piazzale A. Moro, 00185 Roma, Italy
| | - E Ripiccini
- INFN Sezione di Roma, dell'Università "Sapienza", Piazzale A. Moro, 00185 Roma, Italy and Dipartimento di Fisica, dell'Università "Sapienza", Piazzale A. Moro, 00185 Roma, Italy
| | - S Ritt
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland
| | - M Rossella
- INFN Sezione di Pavia, dell'Università, Via Bassi 6, 27100 Pavia, Italy
| | - R Sawada
- ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - F Sergiampietri
- INFN Sezione di Pisa, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - G Signorelli
- INFN Sezione di Pisa, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - S Suzuki
- Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan
| | - F Tenchini
- INFN Sezione di Pisa, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy and Dipartimento di Fisica, dell'Università, Largo B. Pontecorvo 3, 56127 Pisa, Italy
| | - C Topchyan
- University of California, Irvine, California 92697, USA
| | - Y Uchiyama
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland and ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - C Voena
- INFN Sezione di Roma, dell'Università "Sapienza", Piazzale A. Moro, 00185 Roma, Italy
| | - F Xiao
- University of California, Irvine, California 92697, USA
| | - S Yamada
- KEK, High Energy Accelerator Research Organization 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - A Yamamoto
- KEK, High Energy Accelerator Research Organization 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - S Yamashita
- ICEPP, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Z You
- University of California, Irvine, California 92697, USA
| | - Yu V Yudin
- Budker Institute of Nuclear Physics, 630090 Novosibirsk, Russia
| | - D Zanello
- INFN Sezione di Roma, dell'Università "Sapienza", Piazzale A. Moro, 00185 Roma, Italy
| |
Collapse
|
40
|
Slobodianski A, Schmalix S, Perisic T, Astrid K, Frenz J, Hildebrandt M, Machens G. Therapeutic angiogenesis - design and first results of pre-clinical study. Cytotherapy 2013. [DOI: 10.1016/j.jcyt.2013.01.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
41
|
Gürtler L, Bauerfeind U, Blümel J, Burger R, Drosten C, Gröner A, Heiden M, Hildebrandt M, Jansen B, Montag-Lessing T, Offergeld R, Pauli G, Seitz R, Schlenkrich U, Schottstedt V, Strobel J, Willkommen H. Arbonematodes - nematode infections transmissible by arthropods: arbeitskreis blut, untergruppe «bewertung blutassoziierter krankheitserreger»*. ACTA ACUST UNITED AC 2013; 40:50-62. [PMID: 23637651 DOI: 10.1159/000345752] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Accepted: 06/02/2012] [Indexed: 11/19/2022]
|
42
|
Andreev VA, Banks TI, Carey RM, Case TA, Clayton SM, Crowe KM, Deutsch J, Egger J, Freedman SJ, Ganzha VA, Gorringe T, Gray FE, Hertzog DW, Hildebrandt M, Kammel P, Kiburg B, Knaack S, Kravtsov PA, Krivshich AG, Lauss B, Lynch KR, Maev EM, Maev OE, Mulhauser F, Petitjean C, Petrov GE, Prieels R, Schapkin GN, Semenchuk GG, Soroka MA, Tishchenko V, Vasilyev AA, Vorobyov AA, Vznuzdaev ME, Winter P. Measurement of muon capture on the proton to 1% precision and determination of the pseudoscalar coupling gP. Phys Rev Lett 2013; 110:012504. [PMID: 23383785 DOI: 10.1103/physrevlett.110.012504] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Indexed: 06/01/2023]
Abstract
The MuCap experiment at the Paul Scherrer Institute has measured the rate Λ(S) of muon capture from the singlet state of the muonic hydrogen atom to a precision of 1%. A muon beam was stopped in a time projection chamber filled with 10-bar, ultrapure hydrogen gas. Cylindrical wire chambers and a segmented scintillator barrel detected electrons from muon decay. Λ(S) is determined from the difference between the μ(-) disappearance rate in hydrogen and the free muon decay rate. The result is based on the analysis of 1.2 × 10(10) μ(-) decays, from which we extract the capture rate Λ(S) = (714.9 ± 5.4(stat) ± 5.1(syst)) s(-1) and derive the proton's pseudoscalar coupling g(P)(q(0)(2) = -0.88 m(μ)(2)) = 8.06 ± 0.55.
Collapse
Affiliation(s)
- V A Andreev
- Petersburg Nuclear Physics Institute, Gatchina 188350, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Robson RE, Nicoletopoulos P, Hildebrandt M, White RD. Fundamental issues in fluid modeling: Direct substitution and aliasing methods. J Chem Phys 2012; 137:214112. [DOI: 10.1063/1.4768421] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Grothe C, Haastert-Talini K, Freier T, Navarro X, Dahlin LB, Salgado A, Rochkind S, Shahar A, Pinto LFV, Hildebrandt M, Geuna S. BIOHYBRID - Biohybrid templates for peripheral nerve regeneration. J Peripher Nerv Syst 2012; 17:220-2. [PMID: 22734910 DOI: 10.1111/j.1529-8027.2012.00399.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
45
|
Garbe E, Andersohn F, Bronder E, Salama A, Klimpel A, Thomae M, Schrezenmeier H, Hildebrandt M, Späth-Schwalbe E, Grüneisen A, Meyer O, Kurtal H. Drug-induced immune thrombocytopaenia: results from the Berlin Case–Control Surveillance Study. Eur J Clin Pharmacol 2011; 68:821-32. [DOI: 10.1007/s00228-011-1184-3] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2011] [Accepted: 11/22/2011] [Indexed: 10/14/2022]
|
46
|
Adam J, Bai X, Baldini AM, Baracchini E, Bemporad C, Boca G, Cattaneo PW, Cavoto G, Cei F, Cerri C, de Bari A, De Gerone M, Doke T, Dussoni S, Egger J, Fratini K, Fujii Y, Galli L, Gallucci G, Gatti F, Golden B, Grassi M, Grigoriev DN, Haruyama T, Hildebrandt M, Hisamatsu Y, Ignatov F, Iwamoto T, Kettle PR, Khazin BI, Kiselev O, Korenchenko A, Kravchuk N, Maki A, Mihara S, Molzon W, Mori T, Mzavia D, Natori H, Nicolò D, Nishiguchi H, Nishimura Y, Ootani W, Panareo M, Papa A, Pazzi R, Piredda G, Popov A, Renga F, Ritt S, Rossella M, Sawada R, Sergiampietri F, Signorelli G, Suzuki S, Tenchini F, Topchyan C, Uchiyama Y, Valle R, Voena C, Xiao F, Yamada S, Yamamoto A, Yamashita S, Yudin YV, Zanello D. New limit on the lepton-flavor-violating decay μ+→e+γ. Phys Rev Lett 2011; 107:171801. [PMID: 22107507 DOI: 10.1103/physrevlett.107.171801] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/31/2011] [Indexed: 05/31/2023]
Abstract
We present a new result based on an analysis of the data collected by the MEG detector at the Paul Scherrer Institut in 2009 and 2010, in search of the lepton-flavor-violating decay μ(+)e(+)γ. The likelihood analysis of the combined data sample, which corresponds to a total of 1.8×10(14) muon decays, gives a 90% C.L. upper limit of 2.4×10(-12) on the branching ratio of the μ(+)→e(+)γ decay, constituting the most stringent limit on the existence of this decay to date.
Collapse
Affiliation(s)
- J Adam
- Paul Scherrer Institut PSI, CH-5232 Villigen, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Hildebrandt M, Dijkstra D, Gollasch H, Daemen K, Stevanovic-Meyer M, Ludwig WD. Apheresis-related enrichment of CD26++ T lymphocytes: phenotypic characterization and correlation with unfavorable outcome in autologous hematopoietic progenitor cell transplantation. Transfusion 2011; 52:765-76. [DOI: 10.1111/j.1537-2995.2011.03351.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
|
49
|
Garbe E, Andersohn F, Bronder E, Klimpel A, Thomae M, Schrezenmeier H, Hildebrandt M, Späth-Schwalbe E, Grüneisen A, Mayer B, Salama A, Kurtal H. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol 2011; 154:644-53. [PMID: 21749359 DOI: 10.1111/j.1365-2141.2011.08784.x] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Edeltraut Garbe
- Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Bremen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Grotkamp S, Cibis W, Behrens J, Bucher PO, Deetjen W, Nyffeler ID, Gutenbrunner C, Hagen T, Hildebrandt M, Keller K, Nüchtern E, Rentsch HP, Schian H, Schwarze M, Sperling M, Seger W. Personbezogene Faktoren der ICF - Entwurf der AG „ICF” des Fachbereichs II der Deutschen Gesellschaft für Sozialmedizin und Prävention (DGSMP). Gesundheitswesen 2010; 72:908-16. [DOI: 10.1055/s-0030-1268459] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|